Vitamin D nudged cholesterol the right way in women with PCOS

Polycystic ovary syndrome is common, and women who have it often carry an unfavourable cholesterol profile alongside it. Vitamin D deficiency is also prevalent in PCOS, and the relationship between vitamin D status and blood fats appears close, which raises an obvious question: if you correct the vitamin D, do the lipids improve? Individual trials had tested this with supplementation, sometimes alone and sometimes combined with other nutrients, but no single trial settles the question. This meta-analysis set out to pool them and give a clearer answer.

The authors searched Medline, the Cochrane Library, PubMed and Web of Science for trials published before January 2020 in which women with PCOS were assigned at random to vitamin D, either alone or with co-supplementation, or to a comparison. From 954 studies initially identified, 11 trials involving 677 participants qualified for pooling. The team combined the results to estimate effects on total cholesterol, triglycerides, LDL cholesterol, VLDL cholesterol and HDL cholesterol, and ran subgroup analyses by dose, duration and whether vitamin D was given alone or alongside other supplements.

Vitamin D supplementation was associated with reductions in total cholesterol, triglycerides, LDL cholesterol and VLDL cholesterol compared with the comparison groups. HDL cholesterol, by contrast, did not change at all: the pooled estimate sat essentially at zero. The subgroup analyses suggested the picture is not uniform, since the dosage used, how long the intervention ran and whether vitamin D was taken alone or with other supplements all appeared to influence how much the lipids improved. The authors conclude there was a statistical improvement in four of the five lipid measures.

This pooled analysis strengthens the case that vitamin D status and blood fats are connected in PCOS, moving the question beyond single conflicting trials. The null result for HDL is a useful boundary on the claim: whatever vitamin D is doing here, it is not raising the protective cholesterol fraction. The subgroup findings also complicate any simple reading, because the dose and duration that matter most are not pinned down. Open questions remain about which supplementation approach works best and whether the lipid changes translate into health outcomes that matter over years.

For women with PCOS, this is a reason to see vitamin D as relevant to more than bone health: in these pooled trials it was linked to improvements across most of the standard cholesterol panel. It is equally a reason to keep expectations measured, since the effects were modest, HDL did not budge, and the benefit varied with how the supplement was given. Knowing your own vitamin D status, and discussing it in the context of PCOS, is the kind of informed conversation this evidence supports.